Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated and GRADE Assessed Systematic Review and Meta-Analysis of Randomised Controlled Trials.

Authors

Muhammad Huzaifa Khattak, Sohana Memon, Humaira Bibi, Irshad Munir Hassan, Javaria Gul, Kosar Ajmal, Aneeq Mahmood Khan, Danyal Ahmed, Ali Saqlain Saleem, Mohammad Bilal Yousuf, Yasir Mehmood, Hareem Ali, Mehr Afroz, Malik Muhammad Nasr Fayyaz, Tayyaba Ikram Qazi, Bilal Wazir Khan

Published in

Diabetes, obesity & metabolism. Aug 10, 2026. Epub Aug 10, 2026.

Abstract

To evaluate the efficacy and safety of oral PCSK9 inhibitors in adults with hypercholesterolemia by synthesizing evidence from randomised controlled trials.
This systematic review and meta-analysis followed PRISMA guidelines and was registered on PROSPERO (CRD420261303350). PubMed, Embase and Scopus were searched from inception to March 2026 for randomised controlled trials comparing oral PCSK9 inhibitors with placebo in adults with hypercholesterolemia. Primary outcomes were changes in low-density lipoprotein cholesterol (LDL-C) and triglycerides. Secondary outcomes included other lipid parameters, adverse events and mortality. Random-effects models were used to calculate mean differences (MD) and risk ratios (RR) with 95% confidence intervals (CI). Quality of the included studies was assessed using the RoB2 tool and certainty of evidence was assessed using the GRADE approach.
Five randomised controlled trials (n = 4268) were included. Oral PCSK9 inhibitors significantly reduced LDL-C (MD -49.49 mg/dL; 95% CI -54.81 to -44.18; p < 0.00001) and triglycerides (MD -11.65 mg/dL; 95% CI -15.53 to -7.78; p < 0.00001). Significant reductions were also observed in non-HDL cholesterol, apolipoprotein B, lipoprotein(a) and total cholesterol. Dose-dependent effects were noted, with greater reductions at higher doses. No significant differences were observed in mortality or overall adverse events. Treatment discontinuation due to adverse events was lower with intervention.
Oral PCSK9 inhibitors were associated with clinically meaningful improvements in multiple lipid parameters while maintaining a favourable short-term safety profile. However, the available evidence is derived primarily from short-term randomised trials evaluating surrogate lipid outcomes. Larger randomised trials with longer follow-up and cardiovascular outcome data are needed to better define the long-term clinical role of oral PCSK9 inhibitors.

PMID:
42575851
Bibliographic data and abstract were imported from PubMed on 11 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.